Your session is about to expire
← Back to Search
Antiprotozoal Agent
Atovaquone for Ovarian Cancer
Phase 2
Recruiting
Led By Namita Khanna, MD, MSPH
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from initiation of atovaquone to progression or death, assessed up to 1 year
Awards & highlights
Study Summary
This trial tests if repurposed atovaquone can treat ovarian cancer better than existing treatments. It works by stopping the growth of protozoa that cause pneumonia.
Who is the study for?
This trial is for adults with high-grade serous ovarian cancer that has worsened within six months after platinum-based chemotherapy. Participants must be in good physical condition (ECOG status of 0 or 1) and can have had any number of prior treatments. The study welcomes non-English speakers and referrals from community practices.Check my eligibility
What is being tested?
The trial is evaluating the effectiveness of Atovaquone, an antiprotozoal medication typically used to prevent pneumonia, as a new treatment option for patients with platinum-resistant ovarian cancer. It involves procedures like paracentesis, biopsy, and CT scans to monitor the disease's response.See study design
What are the potential side effects?
Atovaquone may cause side effects such as digestive issues (nausea, vomiting), rash, fever, insomnia, coughing and diarrhea. More serious but less common side effects include liver problems and allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from initiation of atovaquone to progression or death, assessed up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from initiation of atovaquone to progression or death, assessed up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression free survival (PFS)
Secondary outcome measures
Clinical benefit rate
Incidence of adverse events
Overall survival (OS)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (atovaquone)Experimental Treatment4 Interventions
Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atovaquone
2012
Completed Phase 1
~80
Biopsy
2014
Completed Phase 4
~1090
Computed Tomography
2017
Completed Phase 2
~2720
Paracentesis
2005
N/A
~80
Find a Location
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,642 Previous Clinical Trials
2,563,978 Total Patients Enrolled
3 Trials studying Ovarian Cancer
420 Patients Enrolled for Ovarian Cancer
National Cancer Institute (NCI)NIH
13,704 Previous Clinical Trials
40,931,414 Total Patients Enrolled
288 Trials studying Ovarian Cancer
73,651 Patients Enrolled for Ovarian Cancer
Namita Khanna, MD, MSPHPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am under 18 years old.My ovarian cancer got worse within 6 months after my last platinum-based treatment.I am unable to make my own medical decisions.I have had any number of previous treatments.I do not speak English.I am fully active or restricted in physically strenuous activity but can do light work.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (atovaquone)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
To what extent may atovaquone endanger patients?
"Treatment (atovaquone) is assessed at a safety score of 2, as this Phase 2 trial has some data supporting its security but none to prove efficacy."
Answered by AI
Are there any opportunities still available for participants in this research?
"At this time, the details of this investigation hosted on clinicaltrials.gov suggest that recruitment is not currently underway; although it was initially posted in September 1st 2023 and most recently updated in August 11th 2023. Despite being inactive at present, there are still 100 other trials enrolling patients presently."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger